{"ticker": {"uuid": "b5e8861c-79ba-484f-a588-f28c65e833f1", "symbol": "MCRB", "name": "Seres Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOSmFaWEZNb1ZrNG91Uk4zUjRJbnRJRHl6aWFzWGJCTkh4Z1JERV9TRi1rVnlTcnNxOWVxNkJMd0VRdHFoQTh5TnA3QmV4UjB3cmk3czlERkM3Y0NXaU9rVzVCcnpUanVyeFhxTmc2SXlkVFF0UGxoZU1Jc0JOYTFUMEtXQUdTOFdEZnpZS05nc00wN1Z0NUNvWUEydGRRaktqRWpVV2luRVp0UnZTcjZLbmJMUE9uM1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:51+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) director receives 6,500 stock options at $7.14 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOU05HemNwN3RBcHVrNnN2cjBBX1JPeXBYaFZIU1RRYmRQbVBmb2ZQamxpVWJpOXVvMXROR2tsQjRTV1FTWlhkdDBqaWllemY1NWJENm1pd1JtZjAyYmlJcFNpZlFyVkxENkQ2cDlJQnVSaFZvMklFTTBRb1V1bWRvRmlOV0QyMUQwU0kxUlhCc2NiVExkbW9SZEQ4S2IzM2Nhb0h5Nkw4cFpZdmRyNUFXdTZrQ3FZRTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:47+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 7,500 stock options to company officer Marella Thorell", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPdVJlOTM0a1BhbmVVQlpES2RWa3hSRHNXVEVqUkFQVUpLZXZXRHNIcGZUSG9Fam10bEkzV1FGYjZWaS1jaDBpRmdxS3ozUzRtdTQ3ZURTRXdxeWliQkVtOW5QcjdfeV9mbnctUXlRMU52Nmt0VGdWamdMSWVwNDczQWRsTWVtV0Mta19UYmVXQ2RHcFFzZlpYNnU5dFJSNlkxbThZVWFTSHB6SGFHbmI3d284dm9RUVU?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:44+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 6,500 stock options to director Claire Fraser", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNai1zcTdmek02TUowbUgzdGN1cndYTnhoYWhBbS1oYURZUFpseXVLZzVLeVlrRmU2RXNKdFdNVDRFaFZJLXpCdFRQYVdQUEMtOWVJNmRkOHBzZG95dkgxUU40LTJhRFdqbzg0UmJOejd2QzJHNUFydlQ3RVQwT0ZiMzJlZUFyazA0OUk1QWlQWV9EWmJUWnBlaTR0d0I2VHg2OTFYLUxrRmNoNUFtQWhrWUw5WlFQMGM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:44+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 6,500 stock options to director Robert L. Rosiello", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPUFVFQlRCc1FXVE9YaFlHekZPN0pNX3J1WGdyNjVqSEpBeUlyLVE2cEQxRnY0Y3pYT1RmN0NaRmtZc1ZlclNocjI2TGRXMThxUURhTkVVRVdDYkU2dm5LZTJsSEsxaVpWTlJvVHY1N0U4OWo5WVRPblhZcG5ncDE2blVVUDYweWU2R2N0bHczZjVOU3BqTk9ROFNadmVYbEtnY21xbkh2OEVjQzlTSk9GMXZaeG9hb2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:42+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOREVnZlVwQXRqRUZiaW9iQmdCN1dpTWM0cC1pNDNnWjc4QzBQMFk5clNfV1lONXNDVzBGWlpmUm5XVVBjN3VwblpWNWZDcV8yaEJJV0VKaEtFaUlscjJTY1piNDlXdUc4elZpX29MZFFHMjMydGxNWUtvVTFCWkdZbzBYM2hpd1lyd3FUUkYxVWoyb1EzS2E3UE82cV9CZlMzcmlfTzEwV0k0SUZSZThYajBWSnE4VGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:34+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 7,500 stock options to officer DesRosier with long vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQQzdSZVJjNUJIY0gwU1A1ckdxaXFzUDdVOFJJTXVWakw1c3VZNm54ck1lbEJpalZ4N01zOWwtXzVTalkwbk5CZHJnX05BOTlMY1l5V002dmI4YkRNOGlZN2Z6empVOEt0cU94WmlGcGRodV9abHViSVgyXzBoWlNTYXptcFVsbFllaHg2ZzhKc3ktS1JrMTBfU0gtVU9kT29scVBZamx6MU8zaGI5eFIteUlWV0VPaDQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:34+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer", "summary": "Seres Therapeutics (MCRB) has granted director and officer Richard N. Kender 50,000 stock options at an exercise price of $9.13 per share. These options will vest in 36 equal monthly installments beginning March 2, 2026, and are set to expire on March 3, 2036. Following this tran", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-0ea95eddd152.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Seres Therapeutics, Inc. Insider Trading Activity", "summary": "Seres Therapeutics, Inc. reported an insider trading activity where officer Brady Kelly received a grant of stock options for 18,750 shares at an exercise price of $9.13 per share. These options will vest over time, with 25% vesting on March 2, 2027, and the remainder in quarterl", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-290898259686.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 25,000-share stock option grant to officer Henn", "summary": "Seres Therapeutics (MCRB) has granted Matthew R. Henn, an officer, 25,000 stock options with an exercise price of $9.13 per share, expiring on March 3, 2036. The options will vest 25% on March 2, 2027, with the remainder vesting in 12 equal quarterly installments, contingent on c", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-4b8bfb2b32e0.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) director Kurt Graves receives 6,500 stock options at $7.14", "summary": "Seres Therapeutics, Inc. director Kurt Graves was granted 6,500 stock options at an exercise price of $7.14 per share, expiring on July 7, 2036. These options will vest on the earlier of July 8, 2027, or the day before the first annual meeting after July 8, 2026, linking the comp", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-96e3f45360b3.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Seres Therapeutics Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing for Seres Therapeutics Inc. (MCRB) dated July 10. Such filings typically disclose transactions by company insiders, and this particular report indicates activity for Seres Therapeutics on that date. The article is brief and primarily serves", "url": "https://ng.investing.com/news/stock-market-news/form-4-seres-therapeutics-inc-for-10-july-93CH-2595489", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14", "summary": "Seres Therapeutics director Eric D. Shaff was granted 6,500 stock options at an exercise price of $7.14 per share, expiring on July 7, 2036. The options will vest on the earlier of July 8, 2027, or the day before the first annual stockholder meeting after July 8, 2026. This grant", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-615749dd2893.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics\u2019 SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study", "summary": "", "url": "https://finance.yahoo.com/m/de553b72-a59c-3e01-80ea-85936388e1e4/seres-therapeutics%E2%80%99-ser-155.html", "source_name": "MarketBeat", "published_at": "2026-07-10T18:02:07+00:00", "published_display": "10 Jul 2026 18:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary", "summary": "Seres Therapeutics presented at the H.C. Wainwright 4th Annual BioConnect Investor Conference, highlighting its novel drug technology, the first FDA-approved oral microbiome drug with an 88% sustained response for C. difficile recurrence, and the integration of generative AI into", "url": "https://quartr.com/events/seres-therapeutics-inc-mcrb-h-c-wainwright-4th-annual-bioconnect-investor-conference_oS22nneq", "source_name": "Quartr", "published_at": "2026-07-09T06:39:16", "published_display": "09 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase", "summary": "Seres Therapeutics, Inc. (NASDAQ: MCRB) shareholders approved all proposals at their reconvened 2026 Annual Meeting, including a significant increase of 900,000 shares to the 2025 Incentive Award Plan. This move aims to allow continued equity-based compensation. Other key approva", "url": "https://www.stocktitan.net/sec-filings/MCRB/8-k-seres-therapeutics-inc-reports-material-event-0e23bf417835.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:11:24", "published_display": "08 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) Q4 2025 earnings summary", "summary": "Seres Therapeutics (MCRB) reported a net income of $5.7 million for 2025, a significant improvement from a $125.8 million net loss in 2024, primarily due to lower operating expenses and the VOWST sale. The company is prioritizing live biotherapeutic programs, especially SER-603 f", "url": "https://quartr.com/events/seres-therapeutics-inc-mcrb-q4-2025_oS22nhtn", "source_name": "Quartr", "published_at": "2026-07-08T20:11:23", "published_display": "08 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment", "summary": "Seres Therapeutics announced early clinical data indicating SER-155's potential to treat immune checkpoint inhibitor-related enterocolitis (irEC) without systemic immunosuppression. The investigator-sponsored trial showed that 80% of patients achieved an immunosuppressive-free cl", "url": "https://finance.yahoo.com/healthcare/articles/seres-therapeutics-announces-early-clinical-110000466.html", "source_name": "Market source", "published_at": "2026-07-08T18:39:59", "published_display": "08 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Seres Therapeutics Stock Falling Today? - Seres Therapeutics (NASDAQ:MCRB)", "summary": "Seres Therapeutics (NASDAQ:MCRB) stock is down today despite the company posting early positive data for its cancer therapy complication treatment, SER-155. The investigational drug, designed to treat immune-related enterocolitis (irEC), showed promising results in an investigato", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60340388/seres-therapeutics-posts-early-data-for-cancer-therapy-complication", "source_name": "Benzinga", "published_at": "2026-07-08T17:11:05", "published_display": "08 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis - Slideshow (NASDAQ:MCRB) 2026-07-08", "summary": "Seres Therapeutics, Inc. (MCRB) released a slide deck discussing promising clinical trial results for its drug SER-155. The trials focus on treating immune checkpoint inhibitor related andropilatis. This information was published by SA Transcripts on Seeking Alpha.", "url": "https://seekingalpha.com/article/4920685-seres-therapeutics-inc-mcrb-discusses-promising-serminus-155-clinical-trial-results-for", "source_name": "Seeking Alpha", "published_at": "2026-07-08T17:00:00", "published_display": "08 Jul 2026 17:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell", "summary": "Seres Therapeutics announced that its Phase 1 clinical trial of SER-155, an investigational microbiome therapeutic, met its primary endpoint for safety and tolerability in patients undergoing allogeneic hematopoietic stem cell transplantation. The trial also demonstrated evidence", "url": "https://www.moomoo.com/news/post/72650516/seres-therapeutics-phase-1-trial-of-ser-155-meets-primary", "source_name": "Moomoo", "published_at": "2026-07-08T13:11:24", "published_display": "08 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics reports positive early SER-155 data", "summary": "Seres Therapeutics announced positive early clinical data for its microbiome candidate SER-155, which showed an 80% immunosuppressive-free clinical response rate and favorable tolerability in a 15-patient study. This investigational treatment aims to modulate the gut microbiome a", "url": "https://grafa.com/en/news/united-states/seres-therapeutics-ser-155-early-clinical-data", "source_name": "grafa.com", "published_at": "2026-07-08T13:11:06", "published_display": "08 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres drug helped 80% of patients in cancer-therapy gut inflammation trial", "summary": "Seres Therapeutics announced positive early clinical data for its drug SER-155 in treating immune checkpoint inhibitor-related enterocolitis (irEC), a severe side effect of cancer therapies. In a 15-patient trial, 80% achieved immunosuppressive-free clinical response at Day 15, w", "url": "https://www.stocktitan.net/news/MCRB/seres-therapeutics-announces-early-clinical-data-showing-potential-e4awg47c4wxx.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:11:06", "published_display": "08 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics outlines its microbiome drug strategy as MCRB works to regain traction", "summary": "Seres Therapeutics is focusing on microbiome-based treatments, with a lead drug candidate aimed at recurrent infections and other early-stage assets for inflammatory conditions. The company's strategy involves heavy investment in clinical trials and manufacturing, emphasizing the", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/seres-therapeutics-outlines-its-microbiome-drug-strategy-as-mcrb-works-to/69714732", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T13:42:09", "published_display": "07 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Seres Therapeutics, Inc. \u2013 NASDAQ:MCRB", "summary": "This article provides financial information for Seres Therapeutics, Inc. (NASDAQ: MCRB), specifically focusing on its price-to-book forward ratio. It briefly mentions the company's stock market listing on Nasdaq and the market status, which was closed at the time of publication. ", "url": "https://www.tradingview.com/symbols/NASDAQ-MCRB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T14:10:55", "published_display": "06 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MCRB - Seres Therapeutics Inc Dividends", "summary": "This article provides a detailed financial overview of Seres Therapeutics Inc. (MCRB), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights various performance indicators and valuation ratios witho", "url": "https://finviz.com/stock?t=MCRB&ta=1&p=d&ty=dv&r=m1", "source_name": "Finviz", "published_at": "2026-07-03T21:39:19", "published_display": "03 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics updates its microbiome drug focus as investors weigh long-term prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQM05kc0NpNTFLck5SOXMyc3RtbzhaNHhkSEdpNElQM3E0LUpNMzRLUDJSZFEtUF83cE4wUnBNelU3UlVNbUZBdkNuYmdnNE03cjJIYk5PN0ZaVzVPZ3FrdFpXeDlTbTlJajBQc2pEQkc0aGtfdnlYdXhCNHNKY1RvTXlaRGxEOUJIcTRBb0RHUHp6dUtIUU5OR3Q0YUFhUzBydnlnY3J5b1B3d2lQZGxFdVAtcVBBNFpBTnpaSmsxekRPMjNQd0tSMHpR?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) director awarded 7,508 stock options vesting by 2027", "summary": "Seres Therapeutics director Dennis A. Ausiello was granted 7,508 stock options with an exercise price of $7.94 per share, expiring in 2036. These options vest in four equal quarterly installments beginning October 2026 and are contingent on his continued service as a non-employee", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-e71519773f8b.html", "source_name": "Stock Titan", "published_at": "2026-07-03T03:34:50", "published_display": "03 Jul 2026 03:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Seres Therapeutics Inc For: 2 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Seres Therapeutics Inc (MCRB) for July 2nd. The brief post includes various market data for indices, commodities, and bonds, alongside trending and most popular articles on Investing.com. It indicates that the company", "url": "https://ca.investing.com/news/stock-market-news/form-4-seres-therapeutics-inc-for-2-july-93CH-4719289", "source_name": "Investing.com Canada", "published_at": "2026-07-02T22:40:50", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (NASDAQ: MCRB) director receives 7,508-share stock option grant", "summary": "Seres Therapeutics director Stephen Berenson was granted stock options covering 7,508 shares of common stock with an exercise price of $7.94 per share. This grant is compensation-related and vests in four equal quarterly installments beginning October 1, 2026, contingent on his c", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-efdc12bbb776.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:40:50", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (NASDAQ: MCRB) director awarded 7,508 stock options at $7.94", "summary": "Seres Therapeutics director Robert L. Rosiello was granted 7,508 stock options at an exercise price of $7.94 per share, as compensation. These options will vest in four equal quarterly installments beginning October 1, 2026, and concluding July 1, 2027, provided he continues his ", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-c943a6901a49.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:40:50", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (Nasdaq:MCRB) - Stock Analysis", "summary": "This Simply Wall St analysis of Seres Therapeutics (MCRB) highlights its clinical-stage focus on biotherapeutics, particularly SER-155 for bloodstream infections and SER-603 for inflammatory bowel disease. The report details the company's financial risks, including less than one ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mcrb/seres-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-30T16:39:19", "published_display": "30 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Seres Therapeutics, Inc. \u2013 NASDAQ:MCRB", "summary": "This article provides an overview of Seres Therapeutics, Inc. (NASDAQ: MCRB), focusing on its enterprise value to revenue forward metric. It appears to be a financial data page from TradingView, offering various financial tools and market data services related to the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-MCRB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:39:54", "published_display": "28 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Seres Therapeutics, Inc. \u2013 NASDAQ:MCRB", "summary": "This article provides financial information for Seres Therapeutics, Inc. (NASDAQ:MCRB), specifically focusing on its price-to-earnings forward metric. The content appears to be a stub or a placeholder, as no specific value or details about the P/E forward are presented beyond the", "url": "https://www.tradingview.com/symbols/NASDAQ-MCRB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:40:51", "published_display": "26 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres\u2019 SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis", "summary": "Seres Therapeutics announced it will host a webcast on July 8, 2026, to present top-line results from an investigator-sponsored trial (IST) of SER-155. The trial evaluated SER-155 for the treatment of immune checkpoint inhibitor-related enterocolitis (irEC), a severe side effect ", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317409/0/en/seres-therapeutics-to-host-webcast-on-july-8-2026-to-discuss-results-of-investigator-sponsored-trial-of-seres-ser-155-in-immune-checkpoint-inhibitor-related-enterocolitis.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T11:11:35", "published_display": "25 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics to discuss SER-155 trial in cancer-side-effect bowel inflammation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaEhnTHNTQXotNEFYNTlvYmpWVXluTDU0MTFWNUFLTk94eVdoM3VuY01ieFdPbDNZcElWaHgydUwyVjJES3dzX3lxRWg1SDdhd0pnT1BtOGc0cTY5YWNBdWVEb1lVemxCWnk4ek5HSkxWb09sbmxsRFp4cDVNZjBxZ0tNQTZuN2JscHpkVm0wRmVIbU04MmVRUmoySkdJR2IzV3FXNGc2N0d6T0lXTmVUUlpVY3p0ZUJ5M290QlNRZTc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics to Host Webcast on July 8, 2026, to", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wJBVV95cUxPUDBUc0Z4R3VSXzZGbEp0VklkOVZjcUowM0l2UFNmazJjcHVQdHZVTVRtMkx3UUdBZ01pOFRBcmFiZHB2eFRPcmE1MXpVMDNXTWFYdW4wN1MtLWd3UUwxQjNQWUJMM1FLR3VnQlZrajdzWVVickU1eGYxX0dzS1VhVGV0NU1JNGZzakVHRTNwRnk4S1dvaGRGblpzLUk5SmsyMjNYS0I3XzZkSjdhS05HbTM4SnV5bndac1dZN1NaRGEzNlpyWlRiR2lXa19id3JGc2tNTHNoUUdZUTJ0akFLVlI3UnJyeEtZU3RzUVlEQVhyckxfblI0eDItOEVRMXZDRkRndjVSdUVjbDNMS0pUZHZraHlmaEExWkVwcS1hRUZ6NlBmd2xfUU5wQWM1SHJ5TzhBdEpEU2xzU2VMZDNKWjY2MElOYk1EOUV6X3FRT2lueEstZUI3MW9FelVQa1U?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating", "summary": "H.C. Wainwright has initiated coverage on Seres Therapeutics (NASDAQ:MCRB) with a buy rating and a price target of $12.00, representing an 82% upside from its current stock price. Seres, a clinical-stage biotech company, develops live biotherapeutic products for inflammatory and ", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-initiates-seres-therapeutics-stock-coverage-with-buy-rating-93CH-4755318", "source_name": "Investing.com", "published_at": "2026-06-23T12:40:31", "published_display": "23 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Seres Therapeutics at Buy With $12 Price Target", "summary": "HC Wainwright has initiated coverage on Seres Therapeutics with a \"Buy\" rating and a $12 price target. The article also briefly mentions Unity Software's fourth-quarter financial results, reporting increased revenue but a quarterly loss.", "url": "https://www.moomoo.com/news/post/71891177/hc-wainwright-initiates-seres-therapeutics-at-buy-with-12-price?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-23T10:40:31", "published_display": "23 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBITDA per share of Seres Therapeutics Inc \u2013 DUS:1S90", "summary": "The article focuses on the EBITDA per share information for Seres Therapeutics Inc, traded on the Dusseldorf Stock Exchange under the symbol 1S90. It provides a financial overview of the company, highlighting that the market is closed with no trades mentioned. The content appears", "url": "https://www.tradingview.com/symbols/DUS-1S90/financials-statistics-and-ratios/ebitda-per-share/", "source_name": "TradingView", "published_at": "2026-06-21T00:10:19", "published_display": "21 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBidkVIRHJfWjJBNHlFdzBhdTdqdHN2c0FZZWEwVGJwLS1vbV9jcDRCWmM3NHlXUnEtQlEtMk5udlhvaGhUZG1hZVB0ZEpKaEV2LV84OEpGdlhmblAzOXEtYk1DSjY2Nl9JOTJTLU1n?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T09:58:17+00:00", "published_display": "18 Jun 2026 09:58", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/were-little-worried-seres-therapeutics-125711080.html", "source_name": "Simply Wall St.", "published_at": "2026-06-13T12:57:11+00:00", "published_display": "13 Jun 2026 12:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/seres-therapeutics-announces-two-transactions-110000621.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T11:00:00+00:00", "published_display": "05 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/seres-therapeutics-participate-h-c-110000912.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Seres Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/seres-therapeutics-q1-earnings-snapshot-111411248.html", "source_name": "Associated Press", "published_at": "2026-05-05T11:14:11+00:00", "published_display": "05 May 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/seres-therapeutics-reports-first-quarter-110000464.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T11:00:00+00:00", "published_display": "05 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Seres Therapeutics (MCRB) Presents Key Data at ESCMID Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPOVB3S29nUUJDaHVuY2NvcnZmYVJvR2Q4RzlEdy1zVlFoTERZM19RcUFMRDA5a2ZKTXR3Q2NSeWFWWkh3WEhPNWNHd0d5alBxV3VmZXlGck5nSVo0OWktNFJmaW05b01MYlJwejQ5U0NwNHRKa1QzNE5Zb3pMa0lrbk5fcHlFOWtQaUczU0tYeGJEdlRfbzBCQUllR3FuWXlsR3JRenpuR3B3NHJfSmU1aA?oc=5", "source_name": "GuruFocus", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPY2IwM0VMdUVLXzN2YzVLYlJSOVA1UV9RbE5aLU1zYU4xMGZjNVpDZVB0VWdtVlg3eVE5Tk9ybXM3X0FMcEhVRWwtRXVtVE5xNC1iVGJvbHZ2Sm03bmpfSmR6Um02Q05xSi1LZjJDWU1lNkN6bVYxSjZ2Z3Z6SVVNNVh5MXBWc3pJMS00SVBoZ2pyZG83QWE0TWpFWGN4VTBYNFZCbHR5czZTMGZ5R2Q0S0pqZmZHRnNiVDYyaTU3SkQ0VEpkdW5HaDZ5RQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOSmFaWEZNb1ZrNG91Uk4zUjRJbnRJRHl6aWFzWGJCTkh4Z1JERV9TRi1rVnlTcnNxOWVxNkJMd0VRdHFoQTh5TnA3QmV4UjB3cmk3czlERkM3Y0NXaU9rVzVCcnpUanVyeFhxTmc2SXlkVFF0UGxoZU1Jc0JOYTFUMEtXQUdTOFdEZnpZS05nc00wN1Z0NUNvWUEydGRRaktqRWpVV2luRVp0UnZTcjZLbmJMUE9uM1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:51+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) director receives 6,500 stock options at $7.14 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOU05HemNwN3RBcHVrNnN2cjBBX1JPeXBYaFZIU1RRYmRQbVBmb2ZQamxpVWJpOXVvMXROR2tsQjRTV1FTWlhkdDBqaWllemY1NWJENm1pd1JtZjAyYmlJcFNpZlFyVkxENkQ2cDlJQnVSaFZvMklFTTBRb1V1bWRvRmlOV0QyMUQwU0kxUlhCc2NiVExkbW9SZEQ4S2IzM2Nhb0h5Nkw4cFpZdmRyNUFXdTZrQ3FZRTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:47+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 7,500 stock options to company officer Marella Thorell", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPdVJlOTM0a1BhbmVVQlpES2RWa3hSRHNXVEVqUkFQVUpLZXZXRHNIcGZUSG9Fam10bEkzV1FGYjZWaS1jaDBpRmdxS3ozUzRtdTQ3ZURTRXdxeWliQkVtOW5QcjdfeV9mbnctUXlRMU52Nmt0VGdWamdMSWVwNDczQWRsTWVtV0Mta19UYmVXQ2RHcFFzZlpYNnU5dFJSNlkxbThZVWFTSHB6SGFHbmI3d284dm9RUVU?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:44+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 6,500 stock options to director Claire Fraser", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNai1zcTdmek02TUowbUgzdGN1cndYTnhoYWhBbS1oYURZUFpseXVLZzVLeVlrRmU2RXNKdFdNVDRFaFZJLXpCdFRQYVdQUEMtOWVJNmRkOHBzZG95dkgxUU40LTJhRFdqbzg0UmJOejd2QzJHNUFydlQ3RVQwT0ZiMzJlZUFyazA0OUk1QWlQWV9EWmJUWnBlaTR0d0I2VHg2OTFYLUxrRmNoNUFtQWhrWUw5WlFQMGM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:44+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 6,500 stock options to director Robert L. Rosiello", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPUFVFQlRCc1FXVE9YaFlHekZPN0pNX3J1WGdyNjVqSEpBeUlyLVE2cEQxRnY0Y3pYT1RmN0NaRmtZc1ZlclNocjI2TGRXMThxUURhTkVVRVdDYkU2dm5LZTJsSEsxaVpWTlJvVHY1N0U4OWo5WVRPblhZcG5ncDE2blVVUDYweWU2R2N0bHczZjVOU3BqTk9ROFNadmVYbEtnY21xbkh2OEVjQzlTSk9GMXZaeG9hb2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:42+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOREVnZlVwQXRqRUZiaW9iQmdCN1dpTWM0cC1pNDNnWjc4QzBQMFk5clNfV1lONXNDVzBGWlpmUm5XVVBjN3VwblpWNWZDcV8yaEJJV0VKaEtFaUlscjJTY1piNDlXdUc4elZpX29MZFFHMjMydGxNWUtvVTFCWkdZbzBYM2hpd1lyd3FUUkYxVWoyb1EzS2E3UE82cV9CZlMzcmlfTzEwV0k0SUZSZThYajBWSnE4VGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:34+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 7,500 stock options to officer DesRosier with long vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQQzdSZVJjNUJIY0gwU1A1ckdxaXFzUDdVOFJJTXVWakw1c3VZNm54ck1lbEJpalZ4N01zOWwtXzVTalkwbk5CZHJnX05BOTlMY1l5V002dmI4YkRNOGlZN2Z6empVOEt0cU94WmlGcGRodV9abHViSVgyXzBoWlNTYXptcFVsbFllaHg2ZzhKc3ktS1JrMTBfU0gtVU9kT29scVBZamx6MU8zaGI5eFIteUlWV0VPaDQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:15:34+00:00", "published_display": "10 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer", "summary": "Seres Therapeutics (MCRB) has granted director and officer Richard N. Kender 50,000 stock options at an exercise price of $9.13 per share. These options will vest in 36 equal monthly installments beginning March 2, 2026, and are set to expire on March 3, 2036. Following this tran", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-0ea95eddd152.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Seres Therapeutics, Inc. Insider Trading Activity", "summary": "Seres Therapeutics, Inc. reported an insider trading activity where officer Brady Kelly received a grant of stock options for 18,750 shares at an exercise price of $9.13 per share. These options will vest over time, with 25% vesting on March 2, 2027, and the remainder in quarterl", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-290898259686.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards 25,000-share stock option grant to officer Henn", "summary": "Seres Therapeutics (MCRB) has granted Matthew R. Henn, an officer, 25,000 stock options with an exercise price of $9.13 per share, expiring on March 3, 2036. The options will vest 25% on March 2, 2027, with the remainder vesting in 12 equal quarterly installments, contingent on c", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-4b8bfb2b32e0.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) director Kurt Graves receives 6,500 stock options at $7.14", "summary": "Seres Therapeutics, Inc. director Kurt Graves was granted 6,500 stock options at an exercise price of $7.14 per share, expiring on July 7, 2036. These options will vest on the earlier of July 8, 2027, or the day before the first annual meeting after July 8, 2026, linking the comp", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-96e3f45360b3.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Seres Therapeutics Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing for Seres Therapeutics Inc. (MCRB) dated July 10. Such filings typically disclose transactions by company insiders, and this particular report indicates activity for Seres Therapeutics on that date. The article is brief and primarily serves", "url": "https://ng.investing.com/news/stock-market-news/form-4-seres-therapeutics-inc-for-10-july-93CH-2595489", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14", "summary": "Seres Therapeutics director Eric D. Shaff was granted 6,500 stock options at an exercise price of $7.14 per share, expiring on July 7, 2036. The options will vest on the earlier of July 8, 2027, or the day before the first annual stockholder meeting after July 8, 2026. This grant", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-615749dd2893.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:16", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics\u2019 SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study", "summary": "", "url": "https://finance.yahoo.com/m/de553b72-a59c-3e01-80ea-85936388e1e4/seres-therapeutics%E2%80%99-ser-155.html", "source_name": "MarketBeat", "published_at": "2026-07-10T18:02:07+00:00", "published_display": "10 Jul 2026 18:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary", "summary": "Seres Therapeutics presented at the H.C. Wainwright 4th Annual BioConnect Investor Conference, highlighting its novel drug technology, the first FDA-approved oral microbiome drug with an 88% sustained response for C. difficile recurrence, and the integration of generative AI into", "url": "https://quartr.com/events/seres-therapeutics-inc-mcrb-h-c-wainwright-4th-annual-bioconnect-investor-conference_oS22nneq", "source_name": "Quartr", "published_at": "2026-07-09T06:39:16", "published_display": "09 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase", "summary": "Seres Therapeutics, Inc. (NASDAQ: MCRB) shareholders approved all proposals at their reconvened 2026 Annual Meeting, including a significant increase of 900,000 shares to the 2025 Incentive Award Plan. This move aims to allow continued equity-based compensation. Other key approva", "url": "https://www.stocktitan.net/sec-filings/MCRB/8-k-seres-therapeutics-inc-reports-material-event-0e23bf417835.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:11:24", "published_display": "08 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) Q4 2025 earnings summary", "summary": "Seres Therapeutics (MCRB) reported a net income of $5.7 million for 2025, a significant improvement from a $125.8 million net loss in 2024, primarily due to lower operating expenses and the VOWST sale. The company is prioritizing live biotherapeutic programs, especially SER-603 f", "url": "https://quartr.com/events/seres-therapeutics-inc-mcrb-q4-2025_oS22nhtn", "source_name": "Quartr", "published_at": "2026-07-08T20:11:23", "published_display": "08 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment", "summary": "Seres Therapeutics announced early clinical data indicating SER-155's potential to treat immune checkpoint inhibitor-related enterocolitis (irEC) without systemic immunosuppression. The investigator-sponsored trial showed that 80% of patients achieved an immunosuppressive-free cl", "url": "https://finance.yahoo.com/healthcare/articles/seres-therapeutics-announces-early-clinical-110000466.html", "source_name": "Market source", "published_at": "2026-07-08T18:39:59", "published_display": "08 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Seres Therapeutics Stock Falling Today? - Seres Therapeutics (NASDAQ:MCRB)", "summary": "Seres Therapeutics (NASDAQ:MCRB) stock is down today despite the company posting early positive data for its cancer therapy complication treatment, SER-155. The investigational drug, designed to treat immune-related enterocolitis (irEC), showed promising results in an investigato", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60340388/seres-therapeutics-posts-early-data-for-cancer-therapy-complication", "source_name": "Benzinga", "published_at": "2026-07-08T17:11:05", "published_display": "08 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis - Slideshow (NASDAQ:MCRB) 2026-07-08", "summary": "Seres Therapeutics, Inc. (MCRB) released a slide deck discussing promising clinical trial results for its drug SER-155. The trials focus on treating immune checkpoint inhibitor related andropilatis. This information was published by SA Transcripts on Seeking Alpha.", "url": "https://seekingalpha.com/article/4920685-seres-therapeutics-inc-mcrb-discusses-promising-serminus-155-clinical-trial-results-for", "source_name": "Seeking Alpha", "published_at": "2026-07-08T17:00:00", "published_display": "08 Jul 2026 17:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell", "summary": "Seres Therapeutics announced that its Phase 1 clinical trial of SER-155, an investigational microbiome therapeutic, met its primary endpoint for safety and tolerability in patients undergoing allogeneic hematopoietic stem cell transplantation. The trial also demonstrated evidence", "url": "https://www.moomoo.com/news/post/72650516/seres-therapeutics-phase-1-trial-of-ser-155-meets-primary", "source_name": "Moomoo", "published_at": "2026-07-08T13:11:24", "published_display": "08 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics reports positive early SER-155 data", "summary": "Seres Therapeutics announced positive early clinical data for its microbiome candidate SER-155, which showed an 80% immunosuppressive-free clinical response rate and favorable tolerability in a 15-patient study. This investigational treatment aims to modulate the gut microbiome a", "url": "https://grafa.com/en/news/united-states/seres-therapeutics-ser-155-early-clinical-data", "source_name": "grafa.com", "published_at": "2026-07-08T13:11:06", "published_display": "08 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres drug helped 80% of patients in cancer-therapy gut inflammation trial", "summary": "Seres Therapeutics announced positive early clinical data for its drug SER-155 in treating immune checkpoint inhibitor-related enterocolitis (irEC), a severe side effect of cancer therapies. In a 15-patient trial, 80% achieved immunosuppressive-free clinical response at Day 15, w", "url": "https://www.stocktitan.net/news/MCRB/seres-therapeutics-announces-early-clinical-data-showing-potential-e4awg47c4wxx.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:11:06", "published_display": "08 Jul 2026 11:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics outlines its microbiome drug strategy as MCRB works to regain traction", "summary": "Seres Therapeutics is focusing on microbiome-based treatments, with a lead drug candidate aimed at recurrent infections and other early-stage assets for inflammatory conditions. The company's strategy involves heavy investment in clinical trials and manufacturing, emphasizing the", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/seres-therapeutics-outlines-its-microbiome-drug-strategy-as-mcrb-works-to/69714732", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T13:42:09", "published_display": "07 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Seres Therapeutics, Inc. \u2013 NASDAQ:MCRB", "summary": "This article provides financial information for Seres Therapeutics, Inc. (NASDAQ: MCRB), specifically focusing on its price-to-book forward ratio. It briefly mentions the company's stock market listing on Nasdaq and the market status, which was closed at the time of publication. ", "url": "https://www.tradingview.com/symbols/NASDAQ-MCRB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T14:10:55", "published_display": "06 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MCRB - Seres Therapeutics Inc Dividends", "summary": "This article provides a detailed financial overview of Seres Therapeutics Inc. (MCRB), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights various performance indicators and valuation ratios witho", "url": "https://finviz.com/stock?t=MCRB&ta=1&p=d&ty=dv&r=m1", "source_name": "Finviz", "published_at": "2026-07-03T21:39:19", "published_display": "03 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics updates its microbiome drug focus as investors weigh long-term prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQM05kc0NpNTFLck5SOXMyc3RtbzhaNHhkSEdpNElQM3E0LUpNMzRLUDJSZFEtUF83cE4wUnBNelU3UlVNbUZBdkNuYmdnNE03cjJIYk5PN0ZaVzVPZ3FrdFpXeDlTbTlJajBQc2pEQkc0aGtfdnlYdXhCNHNKY1RvTXlaRGxEOUJIcTRBb0RHUHp6dUtIUU5OR3Q0YUFhUzBydnlnY3J5b1B3d2lQZGxFdVAtcVBBNFpBTnpaSmsxekRPMjNQd0tSMHpR?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) director awarded 7,508 stock options vesting by 2027", "summary": "Seres Therapeutics director Dennis A. Ausiello was granted 7,508 stock options with an exercise price of $7.94 per share, expiring in 2036. These options vest in four equal quarterly installments beginning October 2026 and are contingent on his continued service as a non-employee", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-e71519773f8b.html", "source_name": "Stock Titan", "published_at": "2026-07-03T03:34:50", "published_display": "03 Jul 2026 03:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Seres Therapeutics Inc For: 2 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Seres Therapeutics Inc (MCRB) for July 2nd. The brief post includes various market data for indices, commodities, and bonds, alongside trending and most popular articles on Investing.com. It indicates that the company", "url": "https://ca.investing.com/news/stock-market-news/form-4-seres-therapeutics-inc-for-2-july-93CH-4719289", "source_name": "Investing.com Canada", "published_at": "2026-07-02T22:40:50", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (NASDAQ: MCRB) director receives 7,508-share stock option grant", "summary": "Seres Therapeutics director Stephen Berenson was granted stock options covering 7,508 shares of common stock with an exercise price of $7.94 per share. This grant is compensation-related and vests in four equal quarterly installments beginning October 1, 2026, contingent on his c", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-efdc12bbb776.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:40:50", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (NASDAQ: MCRB) director awarded 7,508 stock options at $7.94", "summary": "Seres Therapeutics director Robert L. Rosiello was granted 7,508 stock options at an exercise price of $7.94 per share, as compensation. These options will vest in four equal quarterly installments beginning October 1, 2026, and concluding July 1, 2027, provided he continues his ", "url": "https://www.stocktitan.net/sec-filings/MCRB/form-4-seres-therapeutics-inc-insider-trading-activity-c943a6901a49.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:40:50", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (Nasdaq:MCRB) - Stock Analysis", "summary": "This Simply Wall St analysis of Seres Therapeutics (MCRB) highlights its clinical-stage focus on biotherapeutics, particularly SER-155 for bloodstream infections and SER-603 for inflammatory bowel disease. The report details the company's financial risks, including less than one ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mcrb/seres-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-30T16:39:19", "published_display": "30 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Seres Therapeutics, Inc. \u2013 NASDAQ:MCRB", "summary": "This article provides an overview of Seres Therapeutics, Inc. (NASDAQ: MCRB), focusing on its enterprise value to revenue forward metric. It appears to be a financial data page from TradingView, offering various financial tools and market data services related to the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-MCRB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:39:54", "published_display": "28 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Seres Therapeutics, Inc. \u2013 NASDAQ:MCRB", "summary": "This article provides financial information for Seres Therapeutics, Inc. (NASDAQ:MCRB), specifically focusing on its price-to-earnings forward metric. The content appears to be a stub or a placeholder, as no specific value or details about the P/E forward are presented beyond the", "url": "https://www.tradingview.com/symbols/NASDAQ-MCRB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:40:51", "published_display": "26 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres\u2019 SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis", "summary": "Seres Therapeutics announced it will host a webcast on July 8, 2026, to present top-line results from an investigator-sponsored trial (IST) of SER-155. The trial evaluated SER-155 for the treatment of immune checkpoint inhibitor-related enterocolitis (irEC), a severe side effect ", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317409/0/en/seres-therapeutics-to-host-webcast-on-july-8-2026-to-discuss-results-of-investigator-sponsored-trial-of-seres-ser-155-in-immune-checkpoint-inhibitor-related-enterocolitis.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T11:11:35", "published_display": "25 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics to discuss SER-155 trial in cancer-side-effect bowel inflammation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaEhnTHNTQXotNEFYNTlvYmpWVXluTDU0MTFWNUFLTk94eVdoM3VuY01ieFdPbDNZcElWaHgydUwyVjJES3dzX3lxRWg1SDdhd0pnT1BtOGc0cTY5YWNBdWVEb1lVemxCWnk4ek5HSkxWb09sbmxsRFp4cDVNZjBxZ0tNQTZuN2JscHpkVm0wRmVIbU04MmVRUmoySkdJR2IzV3FXNGc2N0d6T0lXTmVUUlpVY3p0ZUJ5M290QlNRZTc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics to Host Webcast on July 8, 2026, to", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wJBVV95cUxPUDBUc0Z4R3VSXzZGbEp0VklkOVZjcUowM0l2UFNmazJjcHVQdHZVTVRtMkx3UUdBZ01pOFRBcmFiZHB2eFRPcmE1MXpVMDNXTWFYdW4wN1MtLWd3UUwxQjNQWUJMM1FLR3VnQlZrajdzWVVickU1eGYxX0dzS1VhVGV0NU1JNGZzakVHRTNwRnk4S1dvaGRGblpzLUk5SmsyMjNYS0I3XzZkSjdhS05HbTM4SnV5bndac1dZN1NaRGEzNlpyWlRiR2lXa19id3JGc2tNTHNoUUdZUTJ0akFLVlI3UnJyeEtZU3RzUVlEQVhyckxfblI0eDItOEVRMXZDRkRndjVSdUVjbDNMS0pUZHZraHlmaEExWkVwcS1hRUZ6NlBmd2xfUU5wQWM1SHJ5TzhBdEpEU2xzU2VMZDNKWjY2MElOYk1EOUV6X3FRT2lueEstZUI3MW9FelVQa1U?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating", "summary": "H.C. Wainwright has initiated coverage on Seres Therapeutics (NASDAQ:MCRB) with a buy rating and a price target of $12.00, representing an 82% upside from its current stock price. Seres, a clinical-stage biotech company, develops live biotherapeutic products for inflammatory and ", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-initiates-seres-therapeutics-stock-coverage-with-buy-rating-93CH-4755318", "source_name": "Investing.com", "published_at": "2026-06-23T12:40:31", "published_display": "23 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Seres Therapeutics at Buy With $12 Price Target", "summary": "HC Wainwright has initiated coverage on Seres Therapeutics with a \"Buy\" rating and a $12 price target. The article also briefly mentions Unity Software's fourth-quarter financial results, reporting increased revenue but a quarterly loss.", "url": "https://www.moomoo.com/news/post/71891177/hc-wainwright-initiates-seres-therapeutics-at-buy-with-12-price?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-23T10:40:31", "published_display": "23 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBITDA per share of Seres Therapeutics Inc \u2013 DUS:1S90", "summary": "The article focuses on the EBITDA per share information for Seres Therapeutics Inc, traded on the Dusseldorf Stock Exchange under the symbol 1S90. It provides a financial overview of the company, highlighting that the market is closed with no trades mentioned. The content appears", "url": "https://www.tradingview.com/symbols/DUS-1S90/financials-statistics-and-ratios/ebitda-per-share/", "source_name": "TradingView", "published_at": "2026-06-21T00:10:19", "published_display": "21 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBidkVIRHJfWjJBNHlFdzBhdTdqdHN2c0FZZWEwVGJwLS1vbV9jcDRCWmM3NHlXUnEtQlEtMk5udlhvaGhUZG1hZVB0ZEpKaEV2LV84OEpGdlhmblAzOXEtYk1DSjY2Nl9JOTJTLU1n?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T09:58:17+00:00", "published_display": "18 Jun 2026 09:58", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/were-little-worried-seres-therapeutics-125711080.html", "source_name": "Simply Wall St.", "published_at": "2026-06-13T12:57:11+00:00", "published_display": "13 Jun 2026 12:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/seres-therapeutics-announces-two-transactions-110000621.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T11:00:00+00:00", "published_display": "05 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/seres-therapeutics-participate-h-c-110000912.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/seres-therapeutics-q1-earnings-snapshot-111411248.html", "source_name": "Associated Press", "published_at": "2026-05-05T11:14:11+00:00", "published_display": "05 May 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/seres-therapeutics-reports-first-quarter-110000464.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T11:00:00+00:00", "published_display": "05 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seres Therapeutics (MCRB) Presents Key Data at ESCMID Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPOVB3S29nUUJDaHVuY2NvcnZmYVJvR2Q4RzlEdy1zVlFoTERZM19RcUFMRDA5a2ZKTXR3Q2NSeWFWWkh3WEhPNWNHd0d5alBxV3VmZXlGck5nSVo0OWktNFJmaW05b01MYlJwejQ5U0NwNHRKa1QzNE5Zb3pMa0lrbk5fcHlFOWtQaUczU0tYeGJEdlRfbzBCQUllR3FuWXlsR3JRenpuR3B3NHJfSmU1aA?oc=5", "source_name": "GuruFocus", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPY2IwM0VMdUVLXzN2YzVLYlJSOVA1UV9RbE5aLU1zYU4xMGZjNVpDZVB0VWdtVlg3eVE5Tk9ybXM3X0FMcEhVRWwtRXVtVE5xNC1iVGJvbHZ2Sm03bmpfSmR6Um02Q05xSi1LZjJDWU1lNkN6bVYxSjZ2Z3Z6SVVNNVh5MXBWc3pJMS00SVBoZ2pyZG83QWE0TWpFWGN4VTBYNFZCbHR5czZTMGZ5R2Q0S0pqZmZHRnNiVDYyaTU3SkQ0VEpkdW5HaDZ5RQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 57, "sentiment_summary": {"positive": 12, "negative": 5, "neutral": 40, "score": 54, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 17.6, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 9.5, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 12, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 6.11, "latest_week": "2026-07-10", "one_week_move": -21.1, "four_week_move": 7.2, "twelve_week_move": -31.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.424995, "market_dynamics_buy_signal": false, "relative_strength": -60.141527, "fair_value_gap": -69.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.9238, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-21.1% over one week, +7.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 18}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com Nigeria", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-21.1% over one week, +7.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere"}], "updated_at": "2026-07-16T11:51:35.103069+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}